Financings in Brief: Rochester Medical
This article was originally published in The Gray Sheet
Rochester Medical: Registration is filed with the Securities and Exchange Commission for a secondary offering of 1.3 mil. shares of common stock to "selected institutional investors." A portion of the proceeds are tabbed for development and commercialization of the Stewartville, Minnesota firm's antibacterial Foley catheter and FemSoft insert for management of female stress incontinence. The remainder of the funds will be used for scale-up of manufacturing facilities, sales force expansion, R&D and for "working capital and other corporate purposes." Vector Securities International is the placement agent for the securities...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.